Literature DB >> 26380573

Dexmedetomidine Infusion to Control Agitation due to Anticholinergic Toxidromes in Adolescents, a Case Series.

Samantha W Gee1, Ada Lin2, Joseph D Tobias3.   

Abstract

Dexmedetomidine is an α2-adrenergic agonist approved by the US Food and Drug Administration for the sedation of adults who are intubated on mechanical ventilation and in non-intubated adults who are undergoing surgical procedures. However, it has also recently become a commonly used sedative agent in varied clinical settings for the pediatric patient as well. We present the use of dexmedetomidine for sedation in a unique clinical scenario, the severely agitated and combative patient following the intentional misuse of anticholinergic drugs. Its applications in this situation are discussed, and previous reports in the literature are reviewed.

Entities:  

Keywords:  adolescent; anticholinergic toxidrome; dexmedetomidine; toxicity

Year:  2015        PMID: 26380573      PMCID: PMC4557723          DOI: 10.5863/1551-6776-20.4.329

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  20 in total

1.  Effect of increasing depth of dexmedetomidine anesthesia on upper airway morphology in children.

Authors:  Mohamed Mahmoud; Rupa Radhakrishman; Joel Gunter; Senthilkumar Sadhasivam; Andrew Schapiro; John McAuliffe; Dean Kurth; Yu Wang; Todd G Nick; Lane F Donnelly
Journal:  Paediatr Anaesth       Date:  2010-04-12       Impact factor: 2.556

2.  Dexmedetomidine for transport of a spontaneously breathing combative child.

Authors:  Kevin M Watt; Jason Walgos; Ira M Cheifetz; David A Turner
Journal:  Pediatrics       Date:  2012-08-13       Impact factor: 7.124

Review 3.  Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology.

Authors:  Joseph D Tobias
Journal:  Pediatr Crit Care Med       Date:  2007-03       Impact factor: 3.624

Review 4.  Dexmedetomidine: antiarrhythmic effects in the pediatric cardiac patient.

Authors:  Joseph D Tobias; Constantinos Chrysostomou
Journal:  Pediatr Cardiol       Date:  2013-02-24       Impact factor: 1.655

5.  Dexmedetomidine use in pediatric intensive care and procedural sedation.

Authors:  Marcia L Buck
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

6.  Novel use of dexmedetomidine for the treatment of anticholinergic toxidrome.

Authors:  Ashley Walker; Andrew Delle Donne; Elizabeth Douglas; Kristine Spicer; Thomas Pluim
Journal:  J Med Toxicol       Date:  2014-12

7.  Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.

Authors:  Andrew J Muzyk; Amber Rayfield; Jane Y Revollo; Heather Heinz; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

Review 8.  Review article: Dexmedetomidine in children: current knowledge and future applications.

Authors:  Keira P Mason; Jerrold Lerman
Journal:  Anesth Analg       Date:  2011-08-04       Impact factor: 5.108

9.  The effects of dexmedetomidine on cardiac electrophysiology in children.

Authors:  Gregory B Hammer; David R Drover; Hong Cao; Ethan Jackson; Glyn D Williams; Chandra Ramamoorthy; George F Van Hare; Alisa Niksch; Anne M Dubin
Journal:  Anesth Analg       Date:  2008-01       Impact factor: 5.108

10.  Effect of dexmedetomidine on the corrected QT and Tp-e intervals during spinal anesthesia.

Authors:  Youngsoon Kim; So Yeon Kim; Jong Seok Lee; Hee Jung Kong; Dong Woo Han
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

View more
  3 in total

1.  Correspondence.

Authors: 
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jul-Aug

2.  Dexmedetomidine as an Adjunct to Treat Anticholinergic Toxidrome in Children.

Authors:  Krista Cowan; Rebecca A Landman; Arun Saini
Journal:  Glob Pediatr Health       Date:  2017-04-24

3.  The Role of Dexmedetomidine in Pediatric Patients Presenting with an Anticholinergic Toxidrome.

Authors:  Mitchell Zekhtser; Erin Carroll; Molly Boyd; Shashikanth Ambati
Journal:  Case Rep Crit Care       Date:  2021-08-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.